- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Large Cap High Growth Potential
Global Pharmaceuticals & Biotech Large Cap High Growth Potential
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
56 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| A302440SK bioscienceLtd | ₩230,500.00 | -1.9% | n/a | ₩17.6t | ₩346,666.67 | PE128.9x | E76.0% | n/a | ||
| 300601Shenzhen Kangtai Biological Products | CN¥105.03 | -1.9% | -40.2% | CN¥72.2b | CN¥204.43 | PE95.4x | E43.8% | 0.6% | ||
| 300896Imeik Technology DevelopmentLtd | CN¥624.00 | 7.8% | 159.4% | CN¥135.0b | CN¥772.90 | PE157.3x | E40.5% | 0.3% | ||
| NVAXNovavax | US$166.25 | 0.5% | 62.9% | US$12.4b | US$264.20 | PS10.5x | E69.2% | n/a | ||
| 661Changchun High & New Technology Industry (Group) | CN¥277.80 | -6.0% | -24.7% | CN¥112.4b | CN¥492.12 | PE30.7x | E23.8% | 0.3% | ||
| 3692Hansoh Pharmaceutical Group | HK$20.00 | -3.4% | -44.2% | HK$118.4b | HK$37.84 | PE37.1x | E22.6% | 0.4% | ||
| 603392Beijing Wantai Biological Pharmacy Enterprise | CN¥235.40 | 6.1% | 81.5% | CN¥142.9b | CN¥339.11 | PE123.8x | E32.7% | 0.08% | ||
| HZNPHorizon Therapeutics | US$112.95 | -0.2% | 44.0% | US$25.5b | US$133.00 | PE49.2x | E57.6% | n/a | ||
| GMABGenmab | kr.2,852.00 | 4.5% | 23.7% | kr.186.5b | kr.2,799.96 | PE74.2x | E36.0% | n/a | ||
| 2821Asymchem Laboratories (Tianjin) | CN¥399.08 | -3.1% | 44.8% | CN¥96.8b | CN¥415.96 | PE115.8x | E31.1% | 0.2% | ||
| 2269WuXi Biologics (Cayman) | HK$114.90 | 2.5% | 72.2% | HK$487.5b | HK$156.26 | PE144.3x | E29.5% | n/a | ||
| TXG10x Genomics | US$154.09 | -1.2% | -5.5% | US$17.1b | US$196.38 | PS42.1x | E52.9% | n/a | ||
| 300142Walvax Biotechnology | CN¥57.63 | -0.5% | 1.8% | CN¥90.3b | n/a | PE71.6x | E26.7% | 0% | ||
| INCYIncyte | US$64.58 | -0.4% | -26.4% | US$14.3b | US$99.00 | PE42.2x | E36.1% | n/a | ||
| AZNAstraZeneca | UK£86.99 | -3.4% | 7.3% | UK£134.8b | UK£100.86 | PE49x | E24.9% | 2.3% | ||
| 1801Innovent Biologics | HK$77.75 | 1.9% | 19.9% | HK$113.5b | HK$95.08 | PS19.6x | E71.4% | n/a | ||
| 688363Bloomage BioTechnology | CN¥172.00 | -6.4% | 28.3% | CN¥82.6b | CN¥257.41 | PE111.7x | E31.8% | 0.2% | ||
| ALNYAlnylam Pharmaceuticals | US$203.90 | -0.3% | 45.0% | US$24.2b | US$189.40 | PS35.2x | E69.6% | n/a | ||
| 300759Pharmaron Beijing | CN¥192.68 | -1.9% | 78.8% | CN¥145.4b | CN¥200.74 | PE121.6x | E26.6% | 0.2% | ||
| 603259WuXi AppTec | CN¥143.70 | 1.3% | 63.4% | CN¥423.6b | CN¥185.18 | PE108.6x | E29.7% | 0.2% | ||
| SGENSeagen | US$171.97 | 6.1% | -13.2% | US$31.3b | US$186.50 | PE52.4x | E70.2% | n/a | ||
| DIMSartorius Stedim Biotech | €471.60 | 9.2% | 52.3% | €43.5b | €444.33 | PE91.5x | E14.2% | 0.1% | ||
| ILMNIllumina | US$410.53 | 1.5% | 27.8% | US$64.2b | US$455.29 | PE83.5x | E30.2% | n/a | ||
| BMYBristol-Myers Squibb | US$56.94 | -0.8% | -6.3% | US$126.5b | US$74.73 | PS2.9x | E25.8% | 3.4% |